Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

The agency wants applicants to demystify their algorithms and provide specific details about what the models do, how they’re ...

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Stay updated on the volatile share price of Recursion, a biotech company with a maturing pipeline and potential for growth ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the company's growth, ...

Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...